Clinical trial
Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor…
NCT00170001 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00170001 |
|---|---|
| Title | Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy |
| Official title | Which Supraesophageal Reflux Symptoms Reliably Respond to PPI Therapy: A Large Simple Trial |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux |
| Intervention type | Drug |
| Interventions | Nexium, Sugar Pill |
| Enrollment | 500 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 15, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: